You are here

Article Text

Article menu

other Versions

Download PDFPDF
Editorial
Deprescribing in the time of covid-19
  1. David Phizackerley, DTB Deputy Editor
  1. DTB, BMJ Journals, London, UK
  1. Correspondence to Mr David Phizackerley, DTB, BMJ Journals, London, UK; dphizackerley{at}bmj.com

https://doi.org/10.1136/dtb.2020.000027

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Since the beginning of December 2019, coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 has challenged populations across the world and resulted in social and economic turmoil. Health services have had to develop new ways of working in order to meet the needs of those with severe covid-19 and maintain ongoing care to all other patients. In the UK, regular media briefings from senior politicians and health professionals have reiterated national public health messages and provided a snapshot of the key issues of the day. While many of the headlines have focused on patient numbers and supplies of personal protective equipment, diagnostic tests and ventilators, rather less attention has been given to managing medicines during the pandemic.

    Nevertheless, stories about the safety of some …

    View Full Text

    Footnotes

    • Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).

    • Provenance and peer review Commissioned; externally peer reviewed.